Regeneron’s fianlimab + Libtayo combo showed 11.5 months PFS vs Keytruda’s 6.4 months in Phase 3 melanoma trial — but missed statistical significance. Analysts are “shaking heads” after the setback.
Regeneron will cut U.S. drug prices, offer free gene therapy for hearing loss, and align costs with other countries under a Trump deal.
AstraZeneca’s experimental drug tozorakimab significantly reduced COPD flare-ups in two Phase 3 trials. Promising new hope for millions of patients with chronic lung disease.
Apogee Therapeutics’ Phase 2 data show zumilokibart maintains strong skin clearance and itch relief in moderate-to-severe eczema for 52 weeks with dosing every 3 or 6 months.
Ocular Therapeutix's (OCUL) Axpaxli outperformed a low dose of Regeneron's Eylea in a late-stage wet AMD trial — but narrower-than-expected margins sent shares crashing 27%, raising serious doubts about its commercial future.
William Blair upgrades Nektar to Outperform following promising long-term data for rezpegaldesleukin in atopic dermatitis treatment with improved safety profile. The results met and in some cases exceeded investor expectations.
